GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients

Enferm Infecc Microbiol Clin. 2011 Dec;29(10):735-58. doi: 10.1016/j.eimc.2011.05.022. Epub 2011 Sep 17.

Abstract

Cytomegalovirus infection remains a major complication of solid organ transplantation. In 2005 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, numerous publications have clarified or questioned the aspects covered in the previous document. These aspects include the situations and populations who must receive prophylaxis and its duration, the selection of the best diagnosis and monitoring technique and the best therapeutic strategy. For these reasons, we have developed new consensus guidelines to include the latest recommendations on post-transplant CMV management based on new evidence available.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus / drug effects
  • Cytomegalovirus / physiology
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / transmission
  • Disease Management
  • Donor Selection
  • Drug Administration Schedule
  • Drug Resistance, Viral
  • Evidence-Based Medicine
  • Humans
  • Immunity, Cellular
  • Immunocompromised Host
  • Risk Factors
  • T-Lymphocyte Subsets / immunology
  • Tissue Donors
  • Transplantation* / adverse effects
  • Viremia / diagnosis
  • Virus Activation / drug effects

Substances

  • Antiviral Agents